| ACAN | Aggrecan |
| ADAMTS | A disintegrin and metalloproteinase with thrombospondin motifs |
| ADAMTS-5 | A disintegrin and metalloproteinase with thrombospondin motifs 5 |
| ADSCs | Adipose-derived stem cells |
| AIA | Adjuvant-induced arthritis |
| ALP | Alkaline phosphatase |
| ASK1 | Apoptosis signal-regulating kinase 1 |
| BMP-2 | Bone morphogenetic protein 2 |
| BMP-7 | Bone morphogenetic protein 7 |
| BMP9 | Bone morphogenetic protein 9 |
| BP | Black phosphorus |
| Bregs | Regulatory B cells |
| BV/TV | Bone volume/tissue volume |
| CCL18 | C-C motif chemokine ligand 18 |
| CD80 | Cluster of differentiation 80 |
| CD86 | Cluster of differentiation 86 |
| CD147 | Basigin/cluster of differentiation 147 |
| CD206 | Cluster of differentiation 206 |
| CFU/g | Colony-forming units per gram |
| CIA | Collagen-induced arthritis |
| COL I | Type I collagen |
| COL II | Type II collagen |
| COL2A | Type II collagen alpha chain marker |
| CQAs | Critical quality attributes |
| CSF1 | Colony-stimulating factor 1 |
| CTSK | Cathepsin K |
| DCs | Dendritic cells |
| DMARD/DMARDs | Disease-modifying antirheumatic drug(s) |
| DNA | Deoxyribonucleic acid |
| DNase I | Deoxyribonuclease I |
| ECM | Extracellular matrix |
| EVs | Extracellular vesicles |
| FAPI | Fibroblast activation protein inhibitor |
| FK506 | Tacrolimus |
| FLS | Fibroblast-like synoviocytes |
| GelMA | Gelatin methacryloyl |
| HA | Hyaluronic acid |
| HAPLN1 | Hyaluronan and proteoglycan link protein 1 |
| H&E | Hematoxylin and eosin |
| HRP | Horseradish peroxidase |
| H2O2 | Hydrogen peroxide |
| H2S | Hydrogen sulfide |
| IDO | Indoleamine 2,3-dioxygenase |
| IFX | Infliximab |
| IGF-1 | Insulin-like growth factor 1 |
| IL-1β | Interleukin-1β |
| IL-4 | Interleukin-4 |
| IL-6 | Interleukin-6 |
| IL-17 | Interleukin-17 |
| IL-32 | Interleukin-32 |
| IL-6/JAK2/STAT3 | Interleukin-6/Janus kinase 2/signal transducer and activator of transcription 3 |
| IND | Indomethacin |
| JAK2 | Janus kinase 2 |
| JNK | c-Jun N-terminal kinase |
| KGN | Kartogenin |
| MAPK | Mitogen-activated protein kinase |
| METTL3 | Methyltransferase-like 3 |
| m6A | N6-methyladenosine |
| miRNA/miRNAs | MicroRNA(s) |
| miR-124-3p | MicroRNA-124-3p |
| miR-140 | MicroRNA-140 |
| miR-195a | MicroRNA-195a |
| miR-221/222 | MicroRNA-221/222 |
| circRNA_28313 | Circular RNA 28313 |
| MMP/MMPs | Matrix metalloproteinase(s) |
| MMP-1 | Matrix metalloproteinase-1 |
| MMP-2 | Matrix metalloproteinase-2 |
| MMP-3/MMP3 | Matrix metalloproteinase-3 |
| MMP-9 | Matrix metalloproteinase-9 |
| MMP-13 | Matrix metalloproteinase-13 |
| MRI | Magnetic resonance imaging |
| MSCs | Mesenchymal stem cells |
| MTX | Methotrexate |
| mRNA | Messenger RNA |
| NET/NETs | Neutrophil extracellular trap(s) |
| NETosis | Neutrophil extracellular trap formation |
| NF-κB | Nuclear factor-κB |
| NFATc1 | Nuclear factor of activated T cells 1 |
| NLRP3 | NOD-like receptor family pyrin domain-containing 3 |
| NO | Nitric oxide |
| NSAIDs | Nonsteroidal anti-inflammatory drugs |
| OA | Osteoarthritis |
| OARSI | Osteoarthritis Research Society International |
| OCN | Osteocalcin |
| OIA | Osteoarthritis-induced arthritis/osteochondral-injury-associated arthritis model, as used in the manuscript context |
| OPG | Osteoprotegerin |
| OVA/CFA | Ovalbumin/complete Freund’s adjuvant |
| PAD4 | Peptidyl arginine deiminase 4 |
| PD-L1 | Programmed death-ligand 1 |
| PGE2 | Prostaglandin E2 |
| PK | Pharmacokinetic(s) |
| PLXNC1 | Plexin C1 |
| PRG4 | Proteoglycan 4 |
| PRP | Platelet-rich plasma |
| PVA | Poly(vinyl alcohol) |
| RA | Rheumatoid arthritis |
| RA-FLS | Rheumatoid arthritis-derived fibroblast-like synoviocytes |
| RANK | Receptor activator of nuclear factor-κB |
| RANKL | Receptor activator of nuclear factor-κB ligand |
| RANKL/OPG | RANKL/osteoprotegerin ratio or balance |
| RANKL/TNF | RANKL/tumor necrosis factor-related strategy |
| RGD | Arginine–glycine–aspartic acid |
| RNA | Ribonucleic acid |
| ROS | Reactive oxygen species |
| RUNX2 | Runt-related transcription factor 2 |
| SAL | Sterility assurance level |
| SIN | Sinomenine hydrochloride |
| SIS | Small intestinal submucosa |
| siRNA | Small interfering RNA |
| SOX9 | SRY-box transcription factor 9 |
| SPARCL1 | Secreted protein acidic and rich in cysteine-like 1 |
| SPD | Spermidine |
| STAT3 | Signal transducer and activator of transcription 3 |
| TAP | Toll-like receptor antagonist peptide |
| Tb.N | Trabecular number |
| Tb.Sp | Trabecular separation |
| Tb.Th | Trabecular thickness |
| TGF-β | Transforming growth factor-β |
| TGF-β3 | Transforming growth factor-β3 |
| Tfh | T follicular helper cell |
| Th17 | T helper 17 cell |
| TLR4 | Toll-like receptor 4 |
| TLRs | Toll-like receptors |
| TNF | Tumor necrosis factor |
| TNF-α | Tumor necrosis factor-α |
| TNFR1 | Tumor necrosis factor receptor 1 |
| TNFR2 | Tumor necrosis factor receptor 2 |
| TPL | Triptolide |
| TRAF | Tumor necrosis factor receptor-associated factor |
| TRAP | Tartrate-resistant acid phosphatase |
| Tregs | Regulatory T cells |
| Tr1 cells | Type 1 regulatory T cells |
| VEGF | Vascular endothelial growth factor |
| W9 | W9 peptide |
| WYRGRL | Cartilage-binding peptide sequence WYRGRL |
| c-Fos | Fos proto-oncogene |
| c-Src | Cellular Src tyrosine kinase |
| micro-CT | Micro-computed tomography |
| Material/system abbreviation | Full term/explanation |
| BiNS/PEI | BiNS/polyethyleneimine nanosheets |
| CeNZs | Cerium-based nanozymes/ceria nanozymes |
| ChSMA | Methacrylated chondroitin sulfate |
| CS/BP | Chitosan/black phosphorus |
| CuS-T | MMP-9-binding CuS-T component |
| Cx-HA | Click-crosslinked hyaluronic acid |
| Cx-SIS | Click-crosslinked small intestinal submucosa |
| DA-HA | Dopamine-modified hyaluronic acid |
| DAGQD | Dopamine-hybrid graphene quantum dots |
| DAGQD@Cu@KGN–SO3−/DA-HA | DAGQD-, Cu-, KGN-, sulfonate-, and DA-HA-based multifunctional hydrogel |
| DNRS | Dual-gas-regulating self-healing hydrogel |
| DS | Diclofenac sodium |
| DSP | Dexamethasone sodium phosphate |
| F127 | Pluronic F127/poloxamer 407 |
| F68 | Pluronic F68/poloxamer 188 |
| Gel-MTX/Mg | Methotrexate- and magnesium-containing supramolecular hydrogel |
| GG | Gellan gum |
| HA–Tyr | Tyramine-modified hyaluronic acid |
| HC@PTM | Composite hydrogel containing MTX-loaded polymeric micelles |
| HP@CEL | Hydrophobically modified HA/celastrol-loaded nanoparticle hydrogel |
| HPAP | HPAP hydrogel system |
| IND–MTX | Indomethacin–methotrexate |
| IND–MTX–siMMP-9 | Indomethacin–methotrexate–MMP-9 siRNA system |
| KGN@P407 | Kartogenin-loaded Pluronic P407 system |
| M-NO | Nitric oxide-responsive or NO-scavenging gel system |
| MOS | Manno-oligosaccharide-modified system |
| NanoIGUR | Iguratimod-loaded nanomicelles |
| PCL | Polycaprolactone |
| PECT | PECT nanoparticles |
| PEG | Polyethylene glycol |
| PEGDMA | Poly(ethylene glycol) dimethacrylate |
| PEI | Polyethyleneimine |
| PEI-SS | Disulfide-containing polyethyleneimine component |
| PGA | Poly(γ-glutamic acid) |
| PLA | Polylactic acid/polylactide |
| PRP–CS/BP | Platelet-rich plasma–chitosan/black phosphorus hydrogel |
| SPT@TPL | Triptolide-loaded dynamically crosslinked hydrogel system |
| TAP/Cx-HA | Toll-like receptor antagonist peptide-loaded click-crosslinked HA hydrogel |
| TAP2 + Cx-HA | TAP2-loaded click-crosslinked HA system |
| Tyr–GG | Tyramine-modified gellan gum |